Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging, and digital biomarkers for CNS drug development. Bringing together biomarker, translational medicine, neuroscience, and clinical development leaders, the summit focuses on accelerating the discovery, validation, and implementation of next-generation biomarkers across neurodegenerative and […]

The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. Bringing together experts from biopharma, biotech, and academia, the summit will explore the latest advances in drug delivery technologies, including nanoparticles, antibody shuttles, gene therapy vectors, […]

The 4th Cell Therapy for Autoimmune Disease Summit is the premier industry forum uniting biopharma leaders, clinical innovators, and scientific pioneers dedicated to advancing the next generation of cell therapies for autoimmune diseases. As the field progresses beyond early proof-of-concept studies and begins to generate increasingly robust clinical data, organizations are shifting their focus toward […]

Antifibrotic Drug Development Summit 2026 | December 1-3, 2026 | Boston, MA, USA The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development, bringing together 60+ senior leaders across discovery, preclinical, translational, biomarker, and early clinical development. This landmark anniversary meeting will explore how shared fibrosis biology, […]

Amylin‑Based Therapeutics Summit | December 1-3, 2026 | Boston, MA The amylin analog space is rapidly expanding in 2026, with new companies entering the field, stealth programs beginning to emerge, and major investment from Roche–Zealand Pharma and AbbVie–Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table, there remains headroom to define best‑in‑class amylin […]

The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted, mechanism-differentiated therapies for neurodegenerative, rare neurodevelopmental, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation, the summit convenes biopharma leaders, translational scientists, and drug developers to explore the next generation of CNS therapeutics and accelerate […]

The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies, developers are focused on identifying the right targets, modalities, and indications to drive differentiation and patient impact. Recent milestones, including Regeneron's cemdisiran advancing […]

Optimizing Tolerability, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development As obesity drug development enters a defining new chapter, the race is no longer about developing the next GLP-1, but delivering the next breakthrough in tolerability, muscle preservation, patient adherence, precision medicine, and long-term outcomes. With hundreds of obesity assets in […]